GlassScriptPhysician profile
Ronald G Steis
NPI 1205875218
$1,318.49
in general payments reported to CMS, 2019-2025
21 companies · $38.27 in 2025
The $38.27 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $226 · 2021: $211 · 2024: $119 · 2025: $38.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $214.00 | 2019 | |
| Abbvie INC. | $177.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $166.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.87 | 2019-2020 | |
| Lilly USA, LLC | $130.87 | 2019-2021 | |
| Pfizer INC. | $118.14 | 2019 | |
| Seagen INC. | $59.14 | 2020-2021 | |
| Foundation Medicine, INC. | $49.01 | 2020 | |
| Glaxosmithkline, LLC. | $38.02 | 2020 | |
| Astellas Pharma US INC | $33.73 | 2020 | |
| Amgen INC. | $32.16 | 2021 | |
| Janssen Biotech, INC. | $28.90 | 2019-2020 | |
| Mylan Institutional INC. | $19.97 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.81 | 2020 | |
| Dova Pharmaceuticals | $16.93 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $16.59 | 2021 | |
| Genzyme Corporation | $15.78 | 2019 | |
| Celgene Corporation | $13.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Steis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.